VA-THREATCONNECT
18.10.2021 12:32:09 CEST | Business Wire | Press release
ThreatConnect Inc.®, the leader in reducing complexity and enabling better decision making in cybersecurity, today released ThreatConnect Risk Quantifier™ 6.0 (RQ 6.0), continuing its innovation in the emerging field of cyber risk quantification.
ThreatConnect Risk Quantifier™ (RQ) enables companies to see the financial risks they face from cyber attacks and also prioritize investments that provide the best ROI. RQ’s calculations are informed by your internal environment, threat intelligence, vulnerability management, operations and response data found within ThreatConnect and other integrations. RQ is distinctly different from other approaches offered in the market as it focuses on automation and data integration, and delivers value in days and weeks as opposed to months and years.
With RQ 6.0 organizations that are looking at financial cyber risk quantification will have the option of leveraging full FAIR scenario’s, using semi-automated FAIR scenario’s, and full automation in one platform.
FAIR is an internationally known standard that has helped companies with awareness and understanding of cyber risk quantification. Organizations implementing FAIR in their CRQ programs have struggled with subjectivity, speed, and actionability, which is why RQ 6.0 is introducing semi-automated FAIR scenario’s that automate a large portion of FAIR in order to reduce complexity and increase time to value for customers.
Semi-Automated FAIR scenarios tackle one of the most challenging aspects of cyber risk quantification - calculating Loss Event Frequency and it’s piece parts. RQ combines data from inside the organization with its own models to evaluate attacker capability against defender strength. Applying this automated calculation to FAIR provides actionable, data-driven results within the FAIR framework and helps organizations transform their manual processes into the scalable, defensible needed to manage the complex risks they face.
“We’ve heard from customers, partners and the broader industry that solutions are needed to address the challenges in adopting and benefiting from CRQ programs,” said ThreatConnect Vice President of Cyber Risk Strategy Gerald Caponera. “Now, through the automation of part of FAIR, organizations can quickly adopt and advance their CRQ programs using their own data combined with ThreatConnect’s analytical capabilities.”
Using a risk-led approach to cybersecurity makes prioritization easy for security teams, enabling them to filter out noise and focus on what matters most. With CRQ, TIP and SOAR capabilities combined, ThreatConnect unifies the actions of the security team around the most critical risks, supports their response with streamlined and automated workflows and strengthens the entire security ecosystem through powerful technology integrations.
Additional details of the release are further outlined in a new blog and video available on the ThreatConnect web site. For more information – click here .
About ThreatConnect
ThreatConnect, Inc. provides cybersecurity software that reduces complexity for everyone, makes decision making easy by turning intelligence into action, and integrates processes and technologies to continually strengthen defenses and drive down risk. Designed by analysts but built for the entire team (security leadership, risk, security operations, threat intelligence, and incident response), ThreatConnect’s decision and operational support platform is the only solution available today with cyber risk quantification, intelligence, automation, analytics, and workflows in one. To learn more about our Cyber Risk Quantification, Threat Intelligence Platform (TIP) or Security Orchestration, Automation, and Response (SOAR) solutions, visit www.ThreatConnect.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
